

Andreas H Groll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7749839/publications.pdf>

Version: 2024-02-01

176
papers

11,993
citations

38742

50
h-index

28297

105
g-index

183
all docs

183
docs citations

183
times ranked

8668
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective surveillance of colonization and disease by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) at a European pediatric cancer center. <i>Supportive Care in Cancer</i> , 2022, 30, 7231-7239.	2.2	2
2	Antimicrobial Use in Pediatric Oncology and Hematology: Protocol for a Multicenter Point-Prevalence Study With Qualitative Expert Panel Assessment. <i>JMIR Research Protocols</i> , 2022, 11, e35774.	1.0	3
3	Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2209-2216.	3.0	1
4	Infections during Non-Neutropenic Episodes in Pediatric Cancer Patients—Results from a Prospective Study in Two Major Large European Cancer Centers. <i>Antibiotics</i> , 2022, 11, 900.	3.7	4
5	Toxoplasmosis after allogeneic haematopoietic cell transplantation—disease burden and approaches to diagnosis, prevention and management in adults and children. <i>Clinical Microbiology and Infection</i> , 2021, 27, 378-388.	6.0	15
6	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1171-1179.	2.4	30
7	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
8	<i>Pneumocystis jirovecii</i> Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, S114-S120.	5.8	50
9	Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality. <i>Antibiotics</i> , 2021, 10, 266.	3.7	23
10	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 186.	3.5	18
11	Extracorporeal Membrane Oxygenation in Children With Cancer or Hematopoietic Cell Transplantation: Single-Center Experience in 20 Consecutive Patients. <i>Frontiers in Oncology</i> , 2021, 11, 664928.	2.8	3
12	Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma. <i>Cancers</i> , 2021, 13, 1990.	3.7	8
13	Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1061-1074.	2.4	15
14	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e254-e269.	10.7	89
15	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e270-e280.	10.7	65
16	Antifungal Combination Therapy in Children with Cancer—A 4-Year Analysis of Real-Life Data of Two Major Pediatric Cancer Centers. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 604.	3.5	1
17	State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul-Ehrlich-Society for Chemotherapy (PEG). <i>Mycoses</i> , 2021, 64, 1177-1182.	4.0	0
18	Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies. <i>Paediatric Drugs</i> , 2021, 23, 445-455.	3.1	1

#	ARTICLE	IF	CITATIONS
19	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
20	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	3.0	15
21	Reply to letter to the Editor to "Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin". <i>Expert Opinion on Drug Safety</i> , 2021, , 1-2.	2.4	0
22	SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients. <i>European Journal of Cancer</i> , 2021, 159, 78-86.	2.8	32
23	<i>Stenotrophomonas maltophilia</i> Infections in Pediatric Patients " Experience at a European Center for Pediatric Hematology and Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 752037.	2.8	10
24	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	3.0	2
25	School and kindergarten attendance and home schooling of pediatric cancer patients before and during the SARS-CoV-2 pandemic: results of a survey of the German Society for Pediatric Oncology and Hematology. <i>GMS Hygiene and Infection Control</i> , 2021, 16, Doc10.	0.3	0
26	Infectious Complications in Paediatric Haematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status. <i>Frontiers in Pediatrics</i> , 2021, 9, 782530.	1.9	7
27	1162. Antifungal Use in Immunocompromised Children in Europe: a 12-week Multicenter Modified Point prevalence Study (CALYPSO). <i>Open Forum Infectious Diseases</i> , 2021, 8, S672-S673.	0.9	1
28	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 226-236.	5.8	84
29	Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. <i>Mycoses</i> , 2020, 63, 172-180.	4.0	15
30	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
31	Etiology and Outcome of Candidemia in Neonates and Children in Europe. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 114-120.	2.0	57
32	Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28702.	1.5	25
33	Invasive Mold Infection of the Central Nervous System in Immunocompromised Children. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 226.	3.5	5
34	Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106084.	2.5	22
35	Systemic viral infection in children receiving chemotherapy for acute leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28673.	1.5	9
36	<i>Candida lusitanae</i> Breakthrough Fungemia in an Immuno-Compromised Adolescent: Case Report and Review of the Literature. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 380.	3.5	10

#	ARTICLE	IF	CITATIONS
37	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 37.	2.4	7
38	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
39	Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland. <i>Infection</i> , 2020, 48, 607-618.	4.7	15
40	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 36.	3.5	15
41	Stepâ€down and move forward. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28342.	1.5	0
42	Therapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status. <i>Handbook of Analytical Separations</i> , 2020, 7, 185-224.	0.8	0
43	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. <i>Arthritis Research and Therapy</i> , 2020, 22, 71.	3.5	25
44	Treatment of Children With Cancer and/or Hematopoietic Stem Cell Transplantation in the Intensive Care Unit: Experience at a Large European Pediatric Cancer Center. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e583-e588.	0.6	10
45	Mykosen. Springer Reference Medizin, 2020, , 1373-1385.	0.0	0
46	Pre-emptive versus empirical antifungal therapy in immunocompromised children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 518-520.	5.6	3
47	Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10â€year experience at a European Pediatric Cancer Center. <i>Mycoses</i> , 2019, 62, 954-960.	4.0	9
48	Moraxella nonliquefaciens bloodstream infection and sepsis in a pediatric cancer patient: case report and literature review. <i>BMC Infectious Diseases</i> , 2019, 19, 836.	2.9	11
49	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
50	Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3573-3578.	3.0	13
51	Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children. <i>Scientific Reports</i> , 2019, 9, 12950.	3.3	15
52	Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27806.	1.5	21
53	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S244-S259.	5.8	40
54	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S260-S274.	5.8	73

#	ARTICLE	IF	CITATIONS
55	Extended Dosing Regimens for Fungal Prophylaxis. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	13.6	17
56	Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study. <i>Frontiers in Microbiology</i> , 2019, 10, 681.	3.5	33
57	A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. <i>PLoS ONE</i> , 2019, 14, e0212837.	2.5	32
58	Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13089.	1.7	8
59	Variability and exposureâ€“response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 761-767.	3.0	48
60	Durable control of hepatitis C through interferonâ€“free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. <i>Journal of Viral Hepatitis</i> , 2019, 26, 454-458.	2.0	3
61	Pediatric Invasive Fungal Infections. , 2019, , 187-203.		0
62	Mykosen bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2019, , 1-13.	0.0	0
63	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
64	Disseminated <i>Bartonella henselae</i> disease mimicking Langerhansâ€™ cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 66, e27573.	1.5	2
65	Toxoplasmosis in Transplant Recipients, Europe, 2010â€“2014. <i>Emerging Infectious Diseases</i> , 2018, 24, 1497-1504.	4.3	94
66	Diagnostic Approaches for Invasive Aspergillosisâ€“Specific Considerations in the Pediatric Population. <i>Frontiers in Microbiology</i> , 2018, 9, 518.	3.5	19
67	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	7.2	86
68	Clinical hepatotoxicity associated with antifungal agents. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-17.	2.4	106
69	Pharmacokinetic Assessment of Drugâ€“Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 76-85.	1.6	101
70	Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. <i>Mycoses</i> , 2017, 60, 493-507.	4.0	10
71	Control of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems. <i>Clinical Infectious Diseases</i> , 2017, 65, 935-942.	5.8	34
72	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017, 102, 433-444.	3.5	468

#	ARTICLE	IF	CITATIONS
73	Epidemiology of Invasive Fungal Disease in Children. Journal of the Pediatric Infectious Diseases Society, 2017, 6, S3-S11.	1.3	144
74	Diagnostic Imaging and Invasive Fungal Diseases in Children. Journal of the Pediatric Infectious Diseases Society, 2017, 6, S22-S31.	1.3	52
75	Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transplant Infectious Disease, 2017, 19, e12751.	1.7	89
76	Vaccination against influenza at a European pediatric cancer center: immunization rates and attitudes among staff, patients, and their families. Supportive Care in Cancer, 2017, 25, 3815-3822.	2.2	9
77	Current Algorithms in Fungal Diagnosis in the Immunocompromised Host. Methods in Molecular Biology, 2017, 1508, 67-84.	0.9	20
78	Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
79	Systemic Antifungal Agents. , 2017, , 1333-1344.e4.		6
80	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology, 2017, 35, 2082-2094.	1.6	337
81	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	1.4	0
82	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infectious Diseases, 2016, 16, 667.	2.9	109
83	Utility of voriconazole therapeutic drug monitoring: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 1786-1799.	3.0	148
84	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2016, 60, 7340-7346.	3.2	35
85	Galactomannan, ¹²⁵ I-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2016, 63, 1340-1348.	5.8	123
86	Biomarker-based diagnostic workup of invasive pulmonary aspergillosis in immunocompromised paediatric patients - is <i>Aspergillus</i> PCR appropriate?. Mycoses, 2016, 59, 67-74.	4.0	16
87	Estimated burden of fungal infections in Germany. Mycoses, 2015, 58, 22-28.	4.0	42
88	Cerebral toxoplasmosis in an adolescent post allogeneic hematopoietic stem cell transplantation: successful outcome by antiprotozoal chemotherapy and $CD4^{+}$ T-lymphocyte recovery. Transplant Infectious Disease, 2015, 17, 119-124.	1.7	11
89	A Prospective, International Cohort Study of Invasive Mold Infections in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 313-322.	1.3	86
90	Clinical Pharmacology of Itraconazole in Children and Adolescents. Current Fungal Infection Reports, 2015, 9, 65-73.	2.6	2

#	ARTICLE	IF	CITATIONS
91	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	14.4	262
92	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. <i>Pharmaceutical Research</i> , 2015, 32, 2029-2037.	3.5	13
93	Invasive candidiasis and candidaemia in neonates and children: update on current guidelines. <i>Mycoses</i> , 2015, 58, 10-21.	4.0	18
94	Medical and Adjunctive Treatment of Mucormycosis in Children: Scientific Rationale and Analysis of Cases Reported in the Literature. <i>Current Fungal Infection Reports</i> , 2014, 8, 12-20.	2.6	0
95	Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 815-820.	3.0	12
96	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. <i>Lancet Oncology</i> , The, 2014, 15, e327-e340.	10.7	325
97	Invasive candidiasis: update on current pharmacotherapy options and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1515-1528.	1.8	27
98	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). <i>Haematologica</i> , 2013, 98, 492-504.	3.5	282
99	Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, E97-E101.	1.7	35
100	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1664-1671.	3.2	44
101	Invasive Aspergillosis in Children and Adolescents. <i>Current Pharmaceutical Design</i> , 2013, 19, 3545-3568.	1.9	13
102	Editorial Commentary: Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 112-115.	1.3	1
103	Invasive Aspergillosis in Children With Acquired Immunodeficiencies. <i>Clinical Infectious Diseases</i> , 2012, 54, 258-267.	5.8	40
104	Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2717-2724.	3.0	44
105	Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1252-1257.	2.0	148
106	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 536-543.	3.2	46
107	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 460-466.	2.0	9
108	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 4427-4438.	1.6	311

#	ARTICLE	IF	CITATIONS
109	Antifungal Chemoprophylaxis in Children and Adolescents with Haematological Malignancies and Following Allogeneic Haematopoietic Stem Cell Transplantation. <i>Drugs</i> , 2012, 72, 685-704.	10.9	51
110	Pharmacokinetics, Safety and Efficacy of Voriconazole in Pediatric Patients: An Update. <i>Current Fungal Infection Reports</i> , 2012, 6, 121-126.	2.6	6
111	Safety of Micafungin in Pediatric Clinical Trials. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e97-e102.	2.0	42
112	Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. <i>Mycoses</i> , 2011, 54, e785-e788.	4.0	47
113	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. <i>Mycoses</i> , 2011, 54, 279-310.	4.0	118
114	Efficacy and safety of antifungals in pediatric patients. <i>Early Human Development</i> , 2011, 87, S71-S74.	1.8	2
115	The Current Role of Posaconazole in Managing Zygomycosis. <i>Current Fungal Infection Reports</i> , 2011, 5, 29-33.	2.6	2
116	Antifungal Therapy in Pediatric Patients. <i>Current Fungal Infection Reports</i> , 2011, 5, 103-110.	2.6	1
117	Echinocandins. , 2011, , 95-112.		4
118	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 415-420.	2.0	135
119	Update on antifungal agents for paediatric patients. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1343-1353.	6.0	42
120	Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4143-4149.	3.2	38
121	Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4116-4123.	3.2	121
122	Antifungal drugs. <i>Side Effects of Drugs Annual</i> , 2010, 32, 491-519.	0.6	0
123	Antifungal agents. , 2010, , 1477-1489.		2
124	Fungal infections in pediatric patients. , 2009, , 481-499.		3
125	Invasive Aspergillosis in Paediatric Patients. , 2009, , 460-483.		0
126	Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 383-387.	3.0	47

#	ARTICLE	IF	CITATIONS
127	Update on invasive opportunistic mycoses: Clinical trials review, 2008â€“2009. Current Infectious Disease Reports, 2009, 11, 417-419.	3.0	1
128	Recent Advances in Antifungal Prevention and Treatment. Seminars in Hematology, 2009, 46, 212-229.	3.4	48
129	SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2009, 28, 1132-1135.	2.0	36
130	Invasive Fungal Infections in Children. Pediatric Infectious Disease Journal, 2009, 28, 734-737.	2.0	49
131	ANTIFUNGAL AGENTS. , 2009, , 3271-3308.		0
132	Invasive opportunistic mycoses: Clinical trials review, 2007â€“2008. Current Infectious Disease Reports, 2008, 10, 451-453.	3.0	0
133	Pediatric pharmacology of antifungal agents. Current Fungal Infection Reports, 2008, 2, 49-56.	2.6	15
134	Experiences with the use of caspofungin in paediatric patients. Mycoses, 2008, 51, 58-64.	4.0	7
135	Posaconazole for paediatric patients: status of development and future perspectives. Mycoses, 2008, 51, 5-11.	4.0	16
136	Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. European Journal of Cancer, 2008, 44, 1861-1865.	2.8	24
137	The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous <i>Candida</i> Meningoencephalitis: Implications for Echinocandin Therapy in Neonates. Journal of Infectious Diseases, 2008, 197, 163-171.	4.0	168
138	Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. Journal of Antimicrobial Chemotherapy, 2008, 61, 734-742.	3.0	53
139	Antifungal drugs. Side Effects of Drugs Annual, 2008, 30, 316-335.	0.6	1
140	Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis. Pediatric Infectious Disease Journal, 2008, 27, 820-826.	2.0	196
141	Caspofungin in pediatric patients. Pediatric Health, 2008, 2, 677-685.	0.3	1
142	Does posaconazole prevent invasive fungal infections in patients with neutropenia?. Nature Clinical Practice Oncology, 2007, 4, 512-513.	4.3	0
143	27 Antifungal drugs. Side Effects of Drugs Annual, 2007, 29, 280-293.	0.6	0
144	Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy, 2007, 8, 2465-2489.	1.8	20

#	ARTICLE	IF	CITATIONS
145	Introduction to Current Fungal Infection Reports. <i>Current Fungal Infection Reports</i> , 2007, 1, 1-2.	2.6	0
146	Invasive fungal infections in children: advances and perspectives. , 2007, , 405-472.		1
147	Infektionserkrankungen. , 2007, , 439-533.		1
148	Linezolid treatment of glycopeptide-resistant <i>Enterococcus faecium</i> in very low birth weight premature neonates. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 256-258.	2.5	14
149	Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. <i>Mycoses</i> , 2006, 49, 7-16.	4.0	29
150	Compartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3418-3423.	3.2	71
151	Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 527-535.	3.0	75
152	Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 899-907.	3.0	23
153	Micafungin: pharmacology, experimental therapeutics and clinical applications. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 489-509.	4.1	35
154	Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5092-5098.	3.2	107
155	Posaconazole: clinical pharmacology and potential for management of fungal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 467-487.	4.4	98
156	Newer Systemic Antifungal Agents. <i>Drugs</i> , 2004, 64, 1997-2020.	10.9	274
157	Clinical pharmacology of antifungal compounds. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 159-191.	5.1	145
158	Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: Synergistic Interaction between an Antifungal Triazole and an Echinocandin. <i>Journal of Infectious Diseases</i> , 2003, 187, 1834-1843.	4.0	238
159	Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 53, 113-114.	3.0	43
160	Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3917-3925.	3.2	14
161	Durable clearance of hepatitis B virus after allogeneic blood stem cell transplantation by adoptive immunity transfer and antiviral chemotherapy. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 753-755.	2.0	2
162	Recent Developments in Epidemiology and Management of Invasive Fungal Infections. , 2003, , 191-213.		1

#	ARTICLE	IF	CITATIONS
163	Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1857-1869.	3.2	178
164	Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2554-2563.	3.2	120
165	Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 240-248.	2.0	476
166	Antifungal chemotherapy: advances and perspectives. <i>Swiss Medical Weekly</i> , 2002, 132, 303-11.	1.6	60
167	Drug therapy in paediatric patients. <i>Lancet, The</i> , 2001, 357, 719.	13.7	4
168	Antifungal Pharmacodynamics: Concentration-Effect Relationships in Vitro and in Vivo. <i>Pharmacotherapy</i> , 2001, 21, 133S-148S.	2.6	66
169	Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 857-869.	3.2	162
170	Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 596-600.	3.2	60
171	Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2845-2855.	3.2	134
172	Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1545-1558.	4.1	123
173	Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental <i>Candida albicans</i> Infection of the Central Nervous System. <i>Journal of Infectious Diseases</i> , 2000, 182, 274-282.	4.0	342
174	Lipid formulations of Amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. <i>Klinische Padiatrie</i> , 1998, 210, 264-273.	0.6	32
175	Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development. <i>Advances in Pharmacology</i> , 1998, 44, 343-500.	2.0	333
176	Antifungal Polyenes. , 0, , 389-415.		0